Yescarta real-world evidence (RWE) study enrolment 2 years ahead of schedule

• Yescarta is the first CAR-T therapy approved by the FDA in the treatment of large B-cell lymphoma
• The Center for International Blood and Marrow Transplant Research and Kite study has reached it’s enrolment target of 1,500 patients 2 years early
• The FDA has required this long-term study for Yescarta which will follow the participants for at least 15 years, generating a wealth of RWE to assess long-term safety and effectiveness

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: OCT2020BR001